Boston Common Asset Management LLC Lowers Stock Position in Gilead Sciences, Inc. $GILD

Boston Common Asset Management LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 122,085 shares of the biopharmaceutical company’s stock after selling 11,043 shares during the period. Boston Common Asset Management LLC’s holdings in Gilead Sciences were worth $13,536,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Clarius Group LLC boosted its position in Gilead Sciences by 5.4% during the 2nd quarter. Clarius Group LLC now owns 8,753 shares of the biopharmaceutical company’s stock worth $970,000 after purchasing an additional 445 shares during the period. AMF Tjanstepension AB boosted its position in Gilead Sciences by 41.7% during the 2nd quarter. AMF Tjanstepension AB now owns 524,960 shares of the biopharmaceutical company’s stock worth $58,244,000 after purchasing an additional 154,530 shares during the period. LGT Fund Management Co Ltd. boosted its position in Gilead Sciences by 14.0% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 28,135 shares of the biopharmaceutical company’s stock worth $3,119,000 after purchasing an additional 3,450 shares during the period. Quent Capital LLC boosted its position in Gilead Sciences by 32.4% during the 2nd quarter. Quent Capital LLC now owns 3,759 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 919 shares during the period. Finally, QRG Capital Management Inc. boosted its position in Gilead Sciences by 6.9% during the 2nd quarter. QRG Capital Management Inc. now owns 299,587 shares of the biopharmaceutical company’s stock worth $33,215,000 after purchasing an additional 19,277 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares in the company, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. The trade was a 1.66% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GILD. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research report on Friday, July 25th. UBS Group upped their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Finally, Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Gilead Sciences Stock Up 1.9%

NASDAQ:GILD opened at $112.69 on Friday. The firm has a market capitalization of $139.83 billion, a PE ratio of 22.45, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. The stock has a 50 day moving average of $114.34 and a 200-day moving average of $109.94. Gilead Sciences, Inc. has a 52 week low of $83.98 and a 52 week high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business’s revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.